The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 studies of 3- and 6-peptide vaccine cocktail derived from GPC3, WDRPUH, and NEIL3 in patients with advanced hepatocellular carcinoma (HCC).
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Nippon Kayaku; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb; Eisai; Kyowa Hakko Kirin; Lilly Japan; NanoCarrier
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Baxter; Bayer Yakuhin; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly Japan; Merck Serono; Nippon Chemiphar Japan; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Izumi Ohno
Consulting or Advisory Role - Merck Serono
 
Shuichi Mitsunaga
Honoraria - Ono Pharmaceutical; Toray Industries
Research Funding - ASLAN Pharmaceuticals; Bayer Yakuhin; Chugai Pharma; Merck Serono
 
Hideaki Takahashi
Honoraria - Bayer; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Shunsuke Kondo
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst)
 
Chigusa Morizane
Honoraria - Fujifilm; Lilly; Nobelpharma; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Eisai (Inst); GlaxoSmithKline (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; J-Pharma; Janssen; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; NanoCarrier; Novartis; OncoTherapy Science; Ono Pharmaceutical; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical